Literature DB >> 22241640

Do topical antibiotics reduce exit site infection rates and peritonitis episodes in peritoneal dialysis patients? The Pan Thames Renal Audit.

Andrew Davenport1.   

Abstract

BACKGROUND AND OBJECTIVES: Peritonitis is the major cause of peritoneal dialysis (PD) technique failure. Prophylactic topical antibiotics have been reported to reduce peritoneal dialysis catheter exit site infections (ESI) and peritonitis rates.
METHODS: We audited the effect of different exit site practices in the 12 Pan Thames and South East England PD centres, on ESIs and peritonitis between 2005 and 2008.
RESULTS: PD patients used prophylactic mupirocin (n=1,270), gentamicin (n=502) and no prophylactic antibiotics (n=1,203); annualised ESI rates were reduced with mupirocin (median 0.18, interquartile range [IQR] 0.13-0.23, patient episodes per year, vs. median 0.32, IQR 0.24-0.69, for no antibiotic prophylaxis, p<0.01). Gentamicin treatment was not significantly lower (median 0.29, IQR 0.21-0.47). Staphylococcal ESIs accounted for 39.6% in the no antibiotic group and fell to 25.7% with mupirocin and 28.2% with gentamicin. Despite the reduction in ESIs, there was no significant reduction in peritonitis rates (no antibiotics: median 0.56, IQR 0.5-0.65; mupirocin: median 0.55, IQR 0.53-0.75; and gentamicin: median 0.47, IQR 0.32-0.65). In particular, mupirocin did not reduce Staphylococcus aureus peritonitis rates.
CONCLUSIONS: Topical antibiotics have been reported to reduce both ESI and peritonitis rates in controlled trials, and although in this audit of routine clinical practice, topical mupirocin did reduce overall ESI rates and both mupirocin and gentamicin reduced S. aureus ESIs, neither reduced overall peritonitis rates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22241640     DOI: 10.5301/jn.5000071

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  7 in total

Review 1.  Peritoneal dialysis-related infections recommendations: 2016 update. What is new?

Authors:  Vassilios Liakopoulos; Olga Nikitidou; Theofanis Kalathas; Stefanos Roumeliotis; Marios Salmas; Theodoros Eleftheriadis
Journal:  Int Urol Nephrol       Date:  2017-06-01       Impact factor: 2.370

Review 2.  [Peritoneal dialysis from the beginnings up to today: which developments of the last decades were important?].

Authors:  Andreas Vychytil
Journal:  Wien Med Wochenschr       Date:  2013-04-17

3.  Use of the embedded peritoneal dialysis catheter.

Authors:  S Sinha; M Fok; A Davenport; N Banga; B Lindsey; B Fernando; C J Forman
Journal:  Ann R Coll Surg Engl       Date:  2018-04-25       Impact factor: 1.891

4.  Reducing the risk of infection in end-stage kidney failure patients treated by dialysis.

Authors:  Sophie Collier; Andrew Davenport
Journal:  Nephrol Dial Transplant       Date:  2014-10-08       Impact factor: 5.992

5.  Comparative Effectiveness of Local Application of Chlorhexidine Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, double-blind, controlled protocol.

Authors:  Surapon Nochaiwong; Chidchanok Ruengorn; Kajohnsak Noppakun; Setthapon Panyathong; Phongsak Dandecha; Manish M Sood; Chalermpong Saenjum; Ratanaporn Awiphan; Sasithorn Sirilun; Pajaree Mongkhon; Wilaiwan Chongruksut; Kednapa Thavorn
Journal:  Trials       Date:  2019-12-19       Impact factor: 2.279

6.  Diagnostic and prognostic role of peritoneal CA 125 in peritoneal dialysis patients presenting with acute peritonitis.

Authors:  Kwanpeemai Panorchan; Andrew Davenport
Journal:  BMC Nephrol       Date:  2014-09-12       Impact factor: 2.388

Review 7.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.